BioSante Pharmaceuticals Reports Positive LibiGel Safety Data Review for Phase III ProgramBioSante Pharmaceuticals Reports Positive LibiGel Safety Data Review for Phase III Program.
Anacor Pharmaceuticals Announces Preliminary Results from Two Safety StudiesAN2728 studies provide positive results, ointment well tolerated on large body surfaces and sensitive skin.
NanoInk Announces Launch of Contract Services Program for Live Single Cell Assay WorkService offering expected to advance research programs involved with toxicity assessment, high content screening, and cell-cell communication.
Neonatal Respiratory Distress Syndrome Treatment Comparison Shows Lower Mortality RatesNew analysis published in eFirst pages of Pediatrics website also shows reduced need for redosing when using CUROSURF Intratracheal Suspension.
Dundee Researchers Seek to Beat "Molecular Obesity"Researchers from the University of Dundee have come up with a new innovative approach in the quest to reduce failure rates in the drug discovery process.
Deutsch Foundation-Sponsored Work Offers Multi-Pronged Attack on Major Medical ProblemResearchers create a microfluidic “lab on a chip” that uses light to monitor biofilm formation and biofilm response to drugs, detects growth and thickening of biofilms by monitoring translucency.
Leading Romanian Research Institution Expands Capabilities With Purchase of a NanoInk DPN 5000 SystemThe DPN 5000 System will be used for supramolecular structure fabrication, molecular recognition and self-assembling process applications.
Infrared Spectroscopy and Microscopy in Cancer Research and DiagnosisThis review illustrates some principles of Fourier transform Infrared vibrational spectroscopy and microscopy as a useful method to interrogate molecules in specimen by mid-IR radiation.
Kadmon Acquires First-in-Class Ras Antagonist from Concordia PharmaceuticalsThe companies announced the signing of an asset purchase agreement under which Kadmon has acquired all rights to salirasib, a Phase 2, novel, orally available, small molecule therapeutic in development for the treatment of solid tumors.
Ikaria INOmax DS Drug Delivery System: FDA Impose Class I Recall - Erratic Nitric Oxide (NO) ReadingsThe erratic readings were being caused by fretting corrosion at the electrical contact interface of certain metals. Adverse consequences may include inadequate oxygen reaching the tissues in the body (hypoxia), low blood pressure (hypotension), slower than normal heart rate (bradycardia), cardiac arrest, organ damage, acute respiratory distress syndrome (ARDS), neurological deficits, or death.
